NCBI_Build	Hugo_Symbol	Variant_Classification	Tumor_Sample_Barcode	HGVSp_Short	HGVSp	HGVSg	Chromosome	Start_Position	End_Position	Reference_Allele	Tumor_Seq_Allele1	Tumor_Seq_Allele2	Variant_Allele_Frequency	Cancer_Type	ANNOTATED	GENE_IN_ONCOKB	VARIANT_IN_ONCOKB	MUTATION_EFFECT	MUTATION_EFFECT_CITATIONS	ONCOGENIC	LEVEL_1	LEVEL_2	LEVEL_3A	LEVEL_3B	LEVEL_4	LEVEL_R1	LEVEL_R2	HIGHEST_LEVEL	HIGHEST_SENSITIVE_LEVEL	HIGHEST_RESISTANCE_LEVEL	TX_CITATIONS	LEVEL_Dx1	LEVEL_Dx2	LEVEL_Dx3	HIGHEST_DX_LEVEL	DX_CITATIONS	LEVEL_Px1	LEVEL_Px2	LEVEL_Px3	HIGHEST_PX_LEVEL	PX_CITATIONS
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.245107176141659	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.235537190082645	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R3			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.176041666666667	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R4			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.231697506033789	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R5			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.036896877956481	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R6			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.21206743566992	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_FLN1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.228813559322034	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0004-SU_T1.R1	p.G719A	p.G719A	c.G2156C	7	55241708	55241708	G	C	C	0.287671232876712	LUAD	True	True	True	Gain-of-function	27294619;21531810;31825714;31931137;26206867;34526717	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0004-SU_T1.R2	p.G719A	p.G719A	c.G2156C	7	55241708	55241708	G	C	C	0.077490774907749	LUAD	True	True	True	Gain-of-function	27294619;21531810;31825714;31931137;26206867;34526717	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0004-SU_T1.R3	p.G719A	p.G719A	c.G2156C	7	55241708	55241708	G	C	C	0.212543554006969	LUAD	True	True	True	Gain-of-function	27294619;21531810;31825714;31931137;26206867;34526717	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0004-SU_T1.R4	p.G719A	p.G719A	c.G2156C	7	55241708	55241708	G	C	C	0.364583333333333	LUAD	True	True	True	Gain-of-function	27294619;21531810;31825714;31931137;26206867;34526717	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0004-BP_LN1	p.G719A	p.G719A	c.G2156C	7	55241708	55241708	G	C	C	0.414772727272727	LUAD	True	True	True	Gain-of-function	27294619;21531810;31825714;31931137;26206867;34526717	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	BRAF	Missense	CRUK0005-SU_T1.R1	p.G466E	p.G466E	c.G1397A	7	140481411	140481411	C	T	T	0.142602495543672	LUAD	True	True	True	Gain-of-function	31515458;27790118;27523909;15046639;28783719;15035987;24446311;28481359	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0005-SU_T1.R2	p.G466E	p.G466E	c.G1397A	7	140481411	140481411	C	T	T	0.149025069637883	LUAD	True	True	True	Gain-of-function	31515458;27790118;27523909;15046639;28783719;15035987;24446311;28481359	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0005-SU_T1.R3	p.G466E	p.G466E	c.G1397A	7	140481411	140481411	C	T	T	0.19496855345912	LUAD	True	True	True	Gain-of-function	31515458;27790118;27523909;15046639;28783719;15035987;24446311;28481359	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0005-SU_T1.R4	p.G466E	p.G466E	c.G1397A	7	140481411	140481411	C	T	T	0.193293885601578	LUAD	True	True	True	Gain-of-function	31515458;27790118;27523909;15046639;28783719;15035987;24446311;28481359	Oncogenic																					
GRCh37	EGFR	In_Frame_Del	CRUK0007-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.071219512195122	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0007-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.157766990291262	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	BRAF	Missense	CRUK0009-SU_T1.R1	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.535714285714286	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0009-SU_T1.R2	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.246753246753247	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0009-SU_T1.R3	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.459259259259259	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0009-SU_T1.R4	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.410112359550562	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0009-SU_FLN1	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.25	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	EGFR	In_Frame_Del	CRUK0010-SU_T1.R1			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.24738219895288	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0010-SU_T1.R2			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.167293233082707	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0010-BR_LN1			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.106451612903226	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0010-BR_LN2			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.08495145631068	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0010-BR_LN3			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.110151187904968	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0010-SU_FLN1			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.104910714285714	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0011-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.151648351648352	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0011-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.262626262626263	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0011-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.315420560747664	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0012-SU_T1.R1			c.2237_2237delins-ATTAAGAGAAGC	7	55242467	55242467	A	-ATTAAGAGAAGC	-ATTAAGAGAAGC	0.13855421686747	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0012-SU_T1.R2			c.2237_2237delins-ATTAAGAGAAGC	7	55242467	55242467	A	-ATTAAGAGAAGC	-ATTAAGAGAAGC	0.112903225806452	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0014-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.312883435582822	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0014-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.141914191419142	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Ins	CRUK0015-SU_T1.R1	p.A767delinsASVS	p.A767delinsASVS	c.2299_2300insCCAGCGTGT	7	55249001	55249001	-	CCAGCGTGT	CCAGCGTGT	0.205128205128205	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0015-SU_T1.R2	p.A767delinsASVS	p.A767delinsASVS	c.2299_2300insCCAGCGTGT	7	55249001	55249001	-	CCAGCGTGT	CCAGCGTGT	0.181034482758621	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	KRAS	Missense	CRUK0017-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.132211538461538	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0017-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.201581027667984	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0017-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.061728395061728	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0018-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.211640211640212	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0018-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.38125	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0018-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.165311653116531	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0018-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.161290322580645	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0019-SU_T1.R1			c.2239_2239delins-TAAGAGAAGCAACATCTC	7	55242469	55242469	T	-TAAGAGAAGCAACATCTC	-TAAGAGAAGCAACATCTC	0.1	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0019-SU_T1.R2			c.2239_2239delins-TAAGAGAAGCAACATCTC	7	55242469	55242469	T	-TAAGAGAAGCAACATCTC	-TAAGAGAAGCAACATCTC	0.227513227513228	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0021-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.817730936143831	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0021-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.802431610942249	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0022-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.391752577319588	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0022-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.4	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0022-SU_FLN1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.368200836820084	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0023-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.224532224532225	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0023-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.214689265536723	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0023-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.226708074534162	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0023-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.122516556291391	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0025-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.462745098039216	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0025-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.597260273972603	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0025-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.329153605015674	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0026-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.198250728862974	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0026-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.239782016348774	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0027-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.172043010752688	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0027-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.154875717017208	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0027-SU_T1.R3	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.065843621399177	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0027-SU_FLN1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.148479427549195	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0030-SU_T2.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.27720207253886	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0030-SU_T2.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.417061611374408	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0030-SU_T2.R3	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.368932038834951	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0032-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.300411522633745	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0032-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.59477866061294	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0032-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.526448362720403	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0032-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.482704402515723	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0034-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.240540540540541	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0034-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.323308270676692	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0034-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.312925170068027	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0035-BP_T1.R1			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.252717391304348	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-BR_T1.R1			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.133689839572193	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_FLN1			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.198717948717949	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_FLN2			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.125628140703518	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_LN01			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.041420118343195	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_T1.R1			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.068364611260054	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_T1.R2			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.084905660377359	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_T1.R3			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.076327433628319	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0035-BP_T1.R1	p.T790M	p.T790M	c.C2369T	7	55249071	55249071	C	T	T	0.255482456140351	LUAD	True	True	True	Gain-of-function	15737014;29151359;15728811;34526717;18227510	Oncogenic	Osimertinib					Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	24478319;26051236;23816963;Yang et al. Abstract# O03.05, IASLC 2013.(http://library.iaslc.org/search-speaker?search_speaker=17991);25923549;30059262;27751847;29151359										
GRCh37	KRAS	Missense	CRUK0036-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.321899736147757	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0036-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.501182033096927	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0036-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.542944785276074	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0036-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.355491329479769	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0036-BR_FLN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.410752688172043	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0037-SU_T1.R1	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.333333333333333	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0037-SU_T1.R2	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.227665706051873	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0037-SU_T1.R3	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.251908396946565	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0037-SU_T1.R4	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.349775784753363	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0037-SU_T1.R5	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.3	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0038-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.126182965299685	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0038-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.17737003058104	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0039-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.41025641025641	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0039-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.358108108108108	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0040-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.067385444743935	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0040-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.075	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	BRAF	Missense	CRUK0041-SU_T1.R1	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.267857142857143	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0041-SU_T1.R2	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.182795698924731	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0041-SU_T1.R3	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.283185840707965	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0041-SU_T1.R4	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.235668789808917	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0041-BR_T1.R1	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.233974358974359	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	KRAS	Missense	CRUK0042-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.115321252059308	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0042-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.069662921348315	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0044-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.055979643765903	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0044-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.032051282051282	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0044-BR_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.187648456057007	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	ERBB2	In_Frame_Ins	CRUK0045-SU_T1.R1	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.128964059196617	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0045-SU_T1.R2	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.049881235154394	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0045-SU_T1.R3	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.078048780487805	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	KRAS	Missense	CRUK0047-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.081521739130435	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0047-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.049079754601227	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0048-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.037220843672457	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0048-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.026134800550206	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0048-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.006105006105006	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0048-SU_T1.R1	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.157894736842105	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0048-SU_T1.R2	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.285211267605634	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0048-SU_T1.R3	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.302547770700637	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0048-BR_T1.R1	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.331428571428571	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0048-BR_T1.R2	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.381720430107527	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0050-SU_T1.R1	p.G12R	p.G12R	c.G34C	12	25398285	25398285	C	G	G	0.434782608695652	LUAD	True	True	True	Gain-of-function	30341394;28572459;22722830;32792368	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0050-SU_T1.R2	p.G12R	p.G12R	c.G34C	12	25398285	25398285	C	G	G	0.358490566037736	LUAD	True	True	True	Gain-of-function	30341394;28572459;22722830;32792368	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0050-SU_T1.R3	p.G12R	p.G12R	c.G34C	12	25398285	25398285	C	G	G	0.343478260869565	LUAD	True	True	True	Gain-of-function	30341394;28572459;22722830;32792368	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0050-SU_T1.R4	p.G12R	p.G12R	c.G34C	12	25398285	25398285	C	G	G	0.296428571428571	LUAD	True	True	True	Gain-of-function	30341394;28572459;22722830;32792368	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0050-SU_T1.R5	p.G12R	p.G12R	c.G34C	12	25398285	25398285	C	G	G	0.18018018018018	LUAD	True	True	True	Gain-of-function	30341394;28572459;22722830;32792368	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0051-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.313218390804598	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0051-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.372505543237251	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0051-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.197204968944099	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0052-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.366247755834829	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0052-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.067567567567568	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0052-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.245080500894454	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0052-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.164345403899721	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0052-SU_FLN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.236363636363636	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0054-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.238866396761134	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0054-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.299319727891156	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0057-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.250639386189258	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0057-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.363892806770099	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0058-SU_T1.R1	p.L861Q	p.L861Q	c.T2582A	7	55259524	55259524	T	A	A	0.358247422680412	LUAD	True	True	True	Gain-of-function	21531810;18508816;29141884;16467085;17177598;25668120;31825714;21841502;15897572;34526717;21252719;19536777;18325048;19147750;26051236;18676761;23912954;24457318;22760226;20808254;23749122;24285021	Oncogenic	Afatinib	Dacomitinib,Erlotinib,Osimertinib,Gefitinib,Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		26051236;22452895;25589191;28336552;23816960;35770100;25668120;37991747;31825714;37879444;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0058-SU_T1.R2	p.L861Q	p.L861Q	c.T2582A	7	55259524	55259524	T	A	A	0.370288248337029	LUAD	True	True	True	Gain-of-function	21531810;18508816;29141884;16467085;17177598;25668120;31825714;21841502;15897572;34526717;21252719;19536777;18325048;19147750;26051236;18676761;23912954;24457318;22760226;20808254;23749122;24285021	Oncogenic	Afatinib	Dacomitinib,Erlotinib,Osimertinib,Gefitinib,Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		26051236;22452895;25589191;28336552;23816960;35770100;25668120;37991747;31825714;37879444;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	KRAS	Missense	CRUK0059-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.130434782608696	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0059-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.168604651162791	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0115-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.09750566893424	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0115-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.420689655172414	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0115-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.103671706263499	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0115-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.512022630834512	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0124-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.16	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0124-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.148773006134969	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0128-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.063903281519862	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0128-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.043189368770764	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R1	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.133451957295374	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R2	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.205776173285199	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R3	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.219709208400646	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R4	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.276661514683153	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R5	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.225806451612903	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R6	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.239737274220033	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R7	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.287414965986395	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R8	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.176470588235294	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	KRAS	Missense	CRUK0159-SU_T1.R1	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.348837209302326	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0159-SU_T1.R2	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.235119047619048	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0159-SU_T1.R3	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.461538461538462	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0182-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.036876355748373	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0182-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.039325842696629	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0206-SU_T1.R1	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.294416243654822	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-SU_T1.R2	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.485436893203884	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-SU_T1.R3	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.261702127659574	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-SU_T1.R4	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.450704225352113	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-SU_T1.R5	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.325490196078431	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-MR_T1.R1	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.474842767295597	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-MR_T1.R2	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.271739130434783	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-MR_T1.R3	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.536666666666667	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-MR_T1.R4	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.266106442577031	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-MR_T1.R5	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.419540229885057	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-SU_FLN1	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.392857142857143	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0212-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.31047619047619	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0212-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.132118451025057	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0223-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.152284263959391	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0223-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.205014749262537	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0233-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.219718309859155	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0233-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.227112676056338	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0247-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.071599045346062	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0247-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.13107822410148	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0259-SU_T1.R1	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.236979166666667	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0259-SU_T1.R2	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.119241192411924	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0267-SU_T1.R1	p.L861Q	p.L861Q	c.T2582A	7	55259524	55259524	T	A	A	0.236754966887417	LUAD	True	True	True	Gain-of-function	21531810;18508816;29141884;16467085;17177598;25668120;31825714;21841502;15897572;34526717;21252719;19536777;18325048;19147750;26051236;18676761;23912954;24457318;22760226;20808254;23749122;24285021	Oncogenic	Afatinib	Dacomitinib,Erlotinib,Osimertinib,Gefitinib,Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		26051236;22452895;25589191;28336552;23816960;35770100;25668120;37991747;31825714;37879444;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0267-SU_T1.R2	p.L861Q	p.L861Q	c.T2582A	7	55259524	55259524	T	A	A	0.480851063829787	LUAD	True	True	True	Gain-of-function	21531810;18508816;29141884;16467085;17177598;25668120;31825714;21841502;15897572;34526717;21252719;19536777;18325048;19147750;26051236;18676761;23912954;24457318;22760226;20808254;23749122;24285021	Oncogenic	Afatinib	Dacomitinib,Erlotinib,Osimertinib,Gefitinib,Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		26051236;22452895;25589191;28336552;23816960;35770100;25668120;37991747;31825714;37879444;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	BRAF	Missense	CRUK0272-SU_T1.R1	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.53030303030303	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0272-SU_T1.R2	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.267942583732057	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0272-SU_T1.R3	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.43598615916955	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0272-SU_T1.R4	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.185	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0272-SU_T1.R5	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.114864864864865	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0274-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.323886639676113	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0274-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.350574712643678	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0274-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.284313725490196	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0274-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.25625	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0276-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.455390334572491	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0276-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.458448753462604	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0276-SU_T1.R3	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.438990182328191	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0280-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.338709677419355	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0280-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.414519906323185	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0280-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.193717277486911	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0280-SU_T1.R4	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.06530612244898	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0280-SU_T1.R5	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.399647887323944	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0284-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.23444976076555	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.205645161290323	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.207920792079208	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.166083916083916	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.273913043478261	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-BP_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.140127388535032	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-BR_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.182741116751269	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0287-SU_T1.R1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.606498194945848	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0287-SU_T1.R2	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.652517275419546	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0297-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.316412859560068	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0297-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.316639741518578	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0297-SU_T1.R3	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.414312617702448	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0297-SU_T1.R4	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.326810176125245	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0297-SU_T1.R5	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.612307692307692	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0299-SU_T1.R1	p.G719C	p.G719C	c.G2155T	7	55241707	55241707	G	T	T	0.450847457627119	LUAD	True	True	True	Likely Gain-of-function	21531810;29141884;15118073;18261621;31825714;31931137;21841502;Chen et al. JCO Precision Oncology 2024 Vol 8, Number 8.(https://ascopubs.org/doi/10.1200/PO.23.00454)	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0299-SU_T1.R2	p.G719C	p.G719C	c.G2155T	7	55241707	55241707	G	T	T	0.435684647302905	LUAD	True	True	True	Likely Gain-of-function	21531810;29141884;15118073;18261621;31825714;31931137;21841502;Chen et al. JCO Precision Oncology 2024 Vol 8, Number 8.(https://ascopubs.org/doi/10.1200/PO.23.00454)	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0299-BR_FLN1	p.G719C	p.G719C	c.G2155T	7	55241707	55241707	G	T	T	0.269230769230769	LUAD	True	True	True	Likely Gain-of-function	21531810;29141884;15118073;18261621;31825714;31931137;21841502;Chen et al. JCO Precision Oncology 2024 Vol 8, Number 8.(https://ascopubs.org/doi/10.1200/PO.23.00454)	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0299-BR_FLN2	p.G719C	p.G719C	c.G2155T	7	55241707	55241707	G	T	T	0.225694444444444	LUAD	True	True	True	Likely Gain-of-function	21531810;29141884;15118073;18261621;31825714;31931137;21841502;Chen et al. JCO Precision Oncology 2024 Vol 8, Number 8.(https://ascopubs.org/doi/10.1200/PO.23.00454)	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0299-SU_FLN1	p.G719C	p.G719C	c.G2155T	7	55241707	55241707	G	T	T	0.228915662650602	LUAD	True	True	True	Likely Gain-of-function	21531810;29141884;15118073;18261621;31825714;31931137;21841502;Chen et al. JCO Precision Oncology 2024 Vol 8, Number 8.(https://ascopubs.org/doi/10.1200/PO.23.00454)	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	KRAS	Missense	CRUK0301-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.116412213740458	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0301-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.074226804123711	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0301-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.048101265822785	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0305-SU_T1.R2	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.088270858524788	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0305-SU_T1.R3	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.236728837876614	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0313-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.156199677938808	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0313-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.233490566037736	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0313-SU_T1.R2	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.096317280453258	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0314-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.192660550458716	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0314-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.177350427350427	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0316-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.384057971014493	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0316-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.25	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0316-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.363192182410423	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0316-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.328313253012048	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0322-SU_T1.R1	p.G13D	p.G13D	c.G38A	12	25398281	25398281	C	T	T	0.005494505494505	LUAD	True	True	True	Gain-of-function	28572459;22722830;32792368;20147967;26037647	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0322-SU_T1.R2	p.G13D	p.G13D	c.G38A	12	25398281	25398281	C	T	T	0.258974358974359	LUAD	True	True	True	Gain-of-function	28572459;22722830;32792368;20147967;26037647	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0322-SU_T1.R3	p.G13D	p.G13D	c.G38A	12	25398281	25398281	C	T	T	0.194006309148265	LUAD	True	True	True	Gain-of-function	28572459;22722830;32792368;20147967;26037647	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0324-SU_T1.R1	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.578260869565217	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0324-SU_T1.R2	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.186666666666667	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0324-SU_T1.R3	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.347517730496454	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	KRAS	Missense	CRUK0333-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.455268389662028	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0333-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.404135338345865	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0333-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.288032454361055	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0337-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.238235294117647	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0337-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.174257425742574	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0337-SU_FLN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.522167487684729	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0339-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.616666666666667	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0339-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.598130841121495	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0339-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.73015873015873	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.667361835245047	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.624321389793703	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.657674418604651	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.399598393574297	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.566236811254396	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R6	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.404086265607264	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R7	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.637281910009183	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.505350772889417	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.321041214750542	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.385737439222042	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.280241935483871	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.46140350877193	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-BR_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.242222222222222	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.057347670250896	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_FLN2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.095121951219512	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_FLN3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.132328308207705	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0366-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.153314917127072	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0366-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.588235294117647	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.058278145695364	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.106471816283925	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.565467625899281	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.710382513661202	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R6	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.328685258964143	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R7	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.057522123893805	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0371-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.25635593220339	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0371-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.280657395701643	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.160060975609756	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.26984126984127	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.123434704830054	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.136442141623489	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.213235294117647	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R6	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.157647058823529	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R7	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.042895442359249	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R8	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.241007194244604	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_T1.R1	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.234817813765182	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_T1.R2	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.25968992248062	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_T1.R3	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.265560165975104	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_T1.R4	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.236947791164659	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_FLN1	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.136986301369863	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_FLN2	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.043478260869565	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	KRAS	Missense	CRUK0408-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.384393063583815	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0408-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.532571428571429	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Ins	CRUK0410-SU_T1.R1	p.M766delinsMASV	p.M766delinsMASV	c.2296_2297insTGGCCAGCG	7	55248998	55248998	-	TGGCCAGCG	TGGCCAGCG	0.24929178470255	LUAD	True	True	False	Likely Gain-of-function	23371856;26286086;24353160;30255937	Likely Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0410-SU_T1.R2	p.M766delinsMASV	p.M766delinsMASV	c.2296_2297insTGGCCAGCG	7	55248998	55248998	-	TGGCCAGCG	TGGCCAGCG	0.249190938511327	LUAD	True	True	False	Likely Gain-of-function	23371856;26286086;24353160;30255937	Likely Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0410-SU_T1.R3	p.M766delinsMASV	p.M766delinsMASV	c.2296_2297insTGGCCAGCG	7	55248998	55248998	-	TGGCCAGCG	TGGCCAGCG	0.264094955489614	LUAD	True	True	False	Likely Gain-of-function	23371856;26286086;24353160;30255937	Likely Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0410-SU_T1.R4	p.M766delinsMASV	p.M766delinsMASV	c.2296_2297insTGGCCAGCG	7	55248998	55248998	-	TGGCCAGCG	TGGCCAGCG	0.173728813559322	LUAD	True	True	False	Likely Gain-of-function	23371856;26286086;24353160;30255937	Likely Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0410-BR_LN1	p.M766delinsMASV	p.M766delinsMASV	c.2296_2297insTGGCCAGCG	7	55248998	55248998	-	TGGCCAGCG	TGGCCAGCG	0.252336448598131	LUAD	True	True	False	Likely Gain-of-function	23371856;26286086;24353160;30255937	Likely Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	KRAS	Missense	CRUK0412-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.431977559607293	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0412-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.419161676646707	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0412-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.394495412844037	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0412-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.434701492537313	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0412-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.631832797427653	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0412-SU_FLN3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.002375296912114	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0413-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.285714285714286	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0413-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.194503171247357	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0416-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.528700906344411	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0416-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.22742474916388	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0416-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.234421364985163	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0431-SU_T1.R1	p.Q61R	p.Q61R	c.A182G	12	25380276	25380276	T	C	C	0.210332103321033	LUAD	True	True	True	Gain-of-function	30341394;28572459;34117033;25437878	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0431-SU_T1.R2	p.Q61R	p.Q61R	c.A182G	12	25380276	25380276	T	C	C	0.240208877284595	LUAD	True	True	True	Gain-of-function	30341394;28572459;34117033;25437878	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0445-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.109034267912773	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0445-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.233727810650888	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0445-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.401253918495298	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0447-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.341991341991342	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0447-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.504918032786885	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0447-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.438953488372093	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0450-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.332425068119891	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0450-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.182648401826484	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0456-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.149722735674677	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0456-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.153846153846154	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0460-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.288311688311688	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0460-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.207627118644068	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0460-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.321243523316062	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0479-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.324055666003976	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0479-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.417439703153989	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0479-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.335164835164835	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0479-SU_T1.R4	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.207459207459207	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	EGFR	In_Frame_Del	CRUK0492-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.089041095890411	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0492-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.088410991636798	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0492-SU_T1.R3			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.076086956521739	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0497-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.691764705882353	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0497-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.802857142857143	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0497-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.822738386308069	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0497-BR_T1.FR1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.705982905982906	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0504-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.462151394422311	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0504-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.557432432432432	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0512-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.368965517241379	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0512-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.386792452830189	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0512-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.249221183800623	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0512-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.379716981132075	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0513-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.802884615384615	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0513-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.752475247524752	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0513-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.159883720930233	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0513-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.708333333333333	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0513-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.055072463768116	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0520-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.1364522417154	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0520-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.138198757763975	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0525-SU_T1.R1			c.2235_2235delins-GAATTAAGAGAAGCA	7	55242465	55242465	G	-GAATTAAGAGAAGCA	-GAATTAAGAGAAGCA	0.165067178502879	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0525-SU_T1.R2			c.2235_2235delins-GAATTAAGAGAAGCA	7	55242465	55242465	G	-GAATTAAGAGAAGCA	-GAATTAAGAGAAGCA	0.203703703703704	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0530-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.170658682634731	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0530-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.438864628820961	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0530-BR_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.093333333333333	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0530-SU_FLN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.212034383954155	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0530-SU_FLN2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.179487179487179	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0533-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.783699059561129	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0533-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.685950413223141	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0533-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.884498480243161	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0533-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.797619047619048	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0537-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.222457627118644	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0537-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.15	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0537-BR_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.197590361445783	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0541-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.52882703777336	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0541-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.534992223950233	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.514851485148515	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.31701030927835	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.481481481481481	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R4	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.453376205787781	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R5	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.466410748560461	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R6	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.453362255965293	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R7	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.389830508474576	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_FLN1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.321041214750542	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_FLN3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.440789473684211	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_FLN5	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.16	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0548-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.291358024691358	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0548-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.323809523809524	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0552-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.412130637636081	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0552-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.489583333333333	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0552-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.401481481481481	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0552-BR_LN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.530903328050713	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0559-SU_LN1	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.319693094629156	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_LN2	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.364820846905537	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_LN3	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.260387811634349	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R1	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.81651376146789	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R2	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.571125265392781	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R3	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.515274949083503	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R4	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.652650822669104	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R5	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.719298245614035	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-BR_T1.R1	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.353070175438596	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_FLN1	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.32409381663113	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_LN1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.310734463276836	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_LN2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.414686825053996	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_LN3	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.27991452991453	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.804245283018868	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.551920341394026	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R3	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.522508038585209	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R4	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.605594405594406	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R5	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.737076648841355	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-BR_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.306338028169014	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_FLN1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.335779816513761	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0569-SU_T1.R1	p.G13D	p.G13D	c.G38A	12	25398281	25398281	C	T	T	0.151927437641723	LUAD	True	True	True	Gain-of-function	28572459;22722830;32792368;20147967;26037647	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0569-SU_T1.R2	p.G13D	p.G13D	c.G38A	12	25398281	25398281	C	T	T	0.029411764705882	LUAD	True	True	True	Gain-of-function	28572459;22722830;32792368;20147967;26037647	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0570-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.344671201814059	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0570-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.339285714285714	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.057471264367816	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.082262210796915	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.111464968152866	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.064748201438849	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.114018691588785	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_FLN2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.162962962962963	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0573-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.561822125813449	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0573-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.368070953436807	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0573-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.553014553014553	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0573-SU_T1.R4	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.525301204819277	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0581-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.082802547770701	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0581-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.032967032967033	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0588-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.116455696202532	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0588-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.650485436893204	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0588-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.143790849673203	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0588-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.33086876155268	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0588-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.069868995633188	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0592-SU_T1.R1	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.441823899371069	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0592-SU_T1.R2	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.309885931558935	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0592-SU_T1.R3	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.389002036659878	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0607-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.270833333333333	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0607-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.234463276836158	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0607-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.262472885032538	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0610-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.082692307692308	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0610-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.121654501216545	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0610-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.195255474452555	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0610-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.09825327510917	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_FLN2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.515260323159785	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_FLN3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.4475	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_LN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.557874762808349	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.479427549194991	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_T2.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.665254237288136	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_T2.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.536704730831974	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_T2.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.607068607068607	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_T2.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.727777777777778	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0625-SU_T1.R1	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.219178082191781	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0625-SU_T1.R2	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.354545454545455	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0625-SU_T1.R3	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.290676416819013	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0625-SU_FLN1	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.13031914893617	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0628-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.086021505376344	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0628-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.174147217235189	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0628-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.327077747989276	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0633-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.149284253578732	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0633-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.157281553398058	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0633-SU_T1.R3	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.294444444444444	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0642-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.074168797953964	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0642-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.101492537313433	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0643-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.05625	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0643-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.171641791044776	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0650-SU_T1.R1	p.Q22K	p.Q22K	c.C64A	12	25398255	25398255	G	T	T	0.903052064631957	LUAD	True	True	True	Gain-of-function	23059812;20570890;26284123;34117033;20949621;11095964	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0650-SU_T1.R2	p.Q22K	p.Q22K	c.C64A	12	25398255	25398255	G	T	T	0.855	LUAD	True	True	True	Gain-of-function	23059812;20570890;26284123;34117033;20949621;11095964	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0650-SU_T1.R3	p.Q22K	p.Q22K	c.C64A	12	25398255	25398255	G	T	T	0.816120906801008	LUAD	True	True	True	Gain-of-function	23059812;20570890;26284123;34117033;20949621;11095964	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.476284584980237	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.29757785467128	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.418823529411765	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R4	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.42369020501139	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R5	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.447058823529412	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R6	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.239005736137667	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_FLN1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.209606986899563	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.311004784688995	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.51270207852194	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.392504930966469	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.325301204819277	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.484087102177554	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R6	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.447463768115942	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R7	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.38663967611336	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R8	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.39589905362776	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_FLN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.285992217898833	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0680-SU_T1.R1	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.435135135135135	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0680-SU_T1.R2	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.189300411522634	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0680-SU_T1.R3	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.518072289156627	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0680-SU_T1.R4	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.17877094972067	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0680-SU_T1.R5	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.47093023255814	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0684-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.163475699558174	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0684-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.190559440559441	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0684-SU_T1.R3			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.121069182389937	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0684-SU_T1.R4			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.161993769470405	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0687-SU_T1.R1	p.G60V	p.G60V	c.G179T	12	25380279	25380279	C	A	A	0.056962025316456	LUAD	True	True	True	Likely Gain-of-function	27288520;24446311;34117033	Likely Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0687-SU_T1.R2	p.G60V	p.G60V	c.G179T	12	25380279	25380279	C	A	A	0.003649635036496	LUAD	True	True	True	Likely Gain-of-function	27288520;24446311;34117033	Likely Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T2.R1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.195704057279236	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T2.R2	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.162227602905569	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T2.R3	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.139841688654354	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T2.R4	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.113785557986871	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T1.R3	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.35048231511254	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T1.R4	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.236923076923077	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T1.R5	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.278571428571429	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.31331592689295	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.258793969849246	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0738-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.292626728110599	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0738-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.275229357798165	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0738-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.272727272727273	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0741-SU_T1.R1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.196787148594378	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0741-SU_T1.R2	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.041420118343195	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0741-SU_T1.R3	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.400943396226415	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0741-SU_T1.R4	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.235294117647059	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_LN2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.22247191011236	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.452423698384201	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.398523985239852	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.429752066115702	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.371428571428571	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.447010869565217	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R6	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.35	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R7	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.090487238979118	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R8	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.467874794069193	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_FLN2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.265861027190332	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_FLN4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.139705882352941	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0755-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.142857142857143	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0755-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.362204724409449	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0756-SU_T1.R1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.283068783068783	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0756-SU_T1.R2	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.537878787878788	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0761-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.465957446808511	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0761-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.494553376906318	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0761-SU_T1.R3	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.472813238770686	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0761-SU_T1.R4	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.432835820895522	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_LN1	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.094915254237288	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_LN2	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.072916666666667	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_T1.R1	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.19327731092437	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_T1.R2	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.205882352941176	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_FLN1	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.082278481012658	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_FLN2	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.055555555555556	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_FLN3	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.05952380952381	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	KRAS	Missense	CRUK0766-SU_T1.R1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.225352112676056	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0766-SU_T1.R2	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.416867469879518	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0766-SU_FLN1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.230046948356808	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0775-SU_T1.R1	p.Q61H	p.Q61H	c.A183C	12	25380275	25380275	T	G	G	0.266409266409266	LUAD	True	True	True	Gain-of-function	24651010;28572459;25705018;34117033;20147967;21993244	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0775-SU_T1.R2	p.Q61H	p.Q61H	c.A183C	12	25380275	25380275	T	G	G	0.263681592039801	LUAD	True	True	True	Gain-of-function	24651010;28572459;25705018;34117033;20147967;21993244	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.157534246575342	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.036697247706422	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.12751677852349	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.178571428571429	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.263285024154589	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R6	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.033492822966507	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R1	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.164285714285714	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R2	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.037433155080214	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R1	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.030470914127424	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R2	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.00635593220339	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R3	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.01909307875895	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R4	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.008830022075055	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R5	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.00251256281407	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R6	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.002717391304348	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	KRAS	Missense	CRUK0810-SU_LN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.230125523012552	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_LN2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.359649122807018	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_LN3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.079320113314448	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.166219839142091	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.25974025974026	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.21474358974359	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.24907063197026	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.315315315315315	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R6	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.237603305785124	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R7	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.2575	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R8	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.196236559139785	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-BR_LN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.163636363636364	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.268733850129199	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0864-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.283116883116883	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0864-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.446969696969697	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0864-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.447826086956522	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0881-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.244186046511628	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0881-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.495726495726496	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0881-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.533333333333333	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0881-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.35258358662614	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0881-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.390977443609023	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0881-SU_T2.R1	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.324712643678161	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0881-SU_T2.R2	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.100671140939597	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0893-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.092838196286472	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0893-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.193704600484261	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0067-SU_T1.R1	p.R68S	p.R68S	c.G204C	12	25380254	25380254	C	G	G	0.138666666666667	LUSC	True	True	True	Likely Gain-of-function	34117033	Likely Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0067-SU_T1.R3	p.R68S	p.R68S	c.G204C	12	25380254	25380254	C	G	G	0.291005291005291	LUSC	True	True	True	Likely Gain-of-function	34117033	Likely Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0069-SU_T1.R1	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.140625	LUSC	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0069-SU_T1.R2	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.045669291338583	LUSC	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0069-SU_T1.R3	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.087759815242494	LUSC	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0069-SU_T1.R4	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.104199066874028	LUSC	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0069-SU_T1.R5	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.097949886104784	LUSC	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0223-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.152284263959391	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0223-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.205014749262537	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0250-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.1889035667107	LUSC	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0250-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.27972027972028	LUSC	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0250-BR_T1.FR1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.325536062378168	LUSC	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R1			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.145998240985048	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R2			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.148339483394834	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R3			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.107960741548528	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R4			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.127450980392157	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R5			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.090614886731392	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R6			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.153259949195597	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R7			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.142105263157895	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0334-SU_T1.R1	p.Q61R	p.Q61R	c.A182G	12	25380276	25380276	T	C	C	0.215384615384615	LUSC	True	True	True	Gain-of-function	30341394;28572459;34117033;25437878	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0334-SU_T1.R2	p.Q61R	p.Q61R	c.A182G	12	25380276	25380276	T	C	C	0.091954022988506	LUSC	True	True	True	Gain-of-function	30341394;28572459;34117033;25437878	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0467-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.014466546112116	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0467-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.185692541856925	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0467-BP_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.405648267008986	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0467-BR_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.14027149321267	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0467-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.137203166226913	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0488-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.095348837209302	LUSC	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0488-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.287211740041929	LUSC	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0528-SU_T1.R1			c.1956_1956delins-GCC	7	55240712	55240712	G	-GCC	-GCC	0.158445440956652	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0528-SU_T1.R2			c.1956_1956delins-GCC	7	55240712	55240712	G	-GCC	-GCC	0.164623467600701	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0528-SU_T1.R3			c.1956_1956delins-GCC	7	55240712	55240712	G	-GCC	-GCC	0.179078014184397	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0528-SU_FLN1			c.1956_1956delins-GCC	7	55240712	55240712	G	-GCC	-GCC	0.125570776255708	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.484334203655352	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.241448692152918	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.654171704957678	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.058651026392962	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.706858407079646	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R6	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.240776699029126	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R7	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.526166902404526	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R8	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.317415730337079	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R1	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.342612419700214	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R2	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.251402918069585	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R3	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.307692307692308	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R4	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.014893617021277	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R5	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.328516377649326	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R6	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.23134328358209	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R7	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.182459677419355	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R8	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.053571428571429	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	BRAF	Missense	CRUK0584-SU_T1.R1	p.T599S	p.T599S	c.A1795T	7	140453140	140453140	T	A	A	0.006711409395973	LUSC	True	True	False	Likely Gain-of-function	19206169;25120313;33019809	Likely Oncogenic																					
GRCh37	BRAF	Missense	CRUK0584-SU_T1.R2	p.T599S	p.T599S	c.A1795T	7	140453140	140453140	T	A	A	0.066326530612245	LUSC	True	True	False	Likely Gain-of-function	19206169;25120313;33019809	Likely Oncogenic																					
GRCh37	BRAF	Missense	CRUK0584-BR_FLN1	p.T599S	p.T599S	c.A1795T	7	140453140	140453140	T	A	A	0.154471544715447	LUSC	True	True	False	Likely Gain-of-function	19206169;25120313;33019809	Likely Oncogenic																					
GRCh37	BRAF	Missense	CRUK0584-SU_FLN1	p.T599S	p.T599S	c.A1795T	7	140453140	140453140	T	A	A	0.132743362831858	LUSC	True	True	False	Likely Gain-of-function	19206169;25120313;33019809	Likely Oncogenic																					
